PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announced that a poster presentation detailing the induction of tumor
specific immunity after intralesional PV-10 treatment was presented by
researchers from the Moffitt Cancer Center at the American Association
for Cancer Research Annual Meeting in Washington, DC.
The poster presentation, based on Abstract #1248 entitled,
"Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune
Response in Murine Models of Breast Cancer and Melanoma," was authored
by Shari Pilon-Thomas1, Amy Weber1, Krithika
Kodumudi1, Lisa Kuhn1, Paul Toomey2 and
Amod A. Sarnaik1 of 1Moffitt Cancer Center, Tampa,
FL and the 2University of South Florida, Tampa, FL.
Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being
examined as a novel cancer therapeutic. It is designed to selectively
target and destroy cancer cells without harming surrounding healthy
tissue, significantly reducing potential for systemic side effects. In
melanoma patients, intralesional (IL) injection of PV-10 has led to
regression of injected lesions as well as distant metastases.
The Moffitt Cancer Center investigational study, which examined the
potential immune mechanism of PV-10 treatment in murine models of breast
cancer and melanoma, demonstrated that injection of PV-10 led to
regression of injected and untreated contralateral subcutaneous lesions,
with a significant increase in survival in mice treated with PV-10. In
related experiments using a melanoma lung metastasis model, mice that
received PV-10 treatment of a cutaneous tumor had markedly fewer lung
metastases compared to controls receiving saline. The poster was
presented by Shari Pilon-Thomas, Ph.D, Immunology Program, Moffitt
Cancer Center.
Dr. Pilon-Thomas commented, “We believe our findings are meaningful
because they confirm the induction of tumor-specific immunity after
single treatment with IL-PV-10 in multiple tumor types. Our data show
that T cells play a crucial roll in this response, and we are continuing
our work to further elucidate the mechanisms that occur following PV-10
treatment.”
Dr. Amod Sarnaik observed, “The systemic response to intralesional PV-10
treatment observed in murine models was sufficiently compelling to
warrant further clinical investigation. We look forward to additional
insights from our current investigational study of the immune mechanism
of PV-10 ablation in cutaneous melanoma patients.”
Additional details on the immunological mechanism of action of PV-10
being presented during the AACR Annual Meeting poster session will be
forthcoming. Abstract #1248 can be accessed at the following link:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=8dc35a86-d973-4f4b-abdd-717b8e5c4096&cKey=f4df7612-2735-462a-956b-1e7c3d81ac33&mKey=%7b9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7d
About the American Association for Cancer Research
The AACR is the oldest and largest scientific organization in the world
focused on every aspect of high-quality, innovative cancer research. Its
reputation for scientific breadth and excellence attract the premier
researchers in the field. The programs and services of the AACR foster
the exchange of knowledge and new ideas among scientists dedicated to
cancer research, provide training opportunities for the next generation
of cancer researchers, and increase public understanding of cancer.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
